An interventional study of continuous thetaburst stimulation in Epilepsies, Partial, sponsored by University Hospital, Ghent. Terminated at 1 site in Belgium. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-02-15.
Sponsored by University Hospital, Ghent · Not applicable, Interventional, and Treatment
The purpose of this study is to investigate a novel stimulation protocol of repetitive transcranial magnetic stimulation (rTMS) for the treatment of unifocal neocortical epilepsy, namely continuous thetaburst stimulation (cTBS). As this is a pilot study, the primary endpoint is on safety and tolerability of the treatment. However, information on clinical efficacy and mechanism of action will also be collected.
Study design:
This is an open label prospective pilot trial of continuous thetaburst stimulation (cTBS) in patients with unifocal neocortical epilepsy.
The study comprises a 13-week period, consisting of 4 weeks baseline seizure frequency assessment, a one-week treatment period with baseline assessments on Monday (T0) and stimulation sessions from Tuesday to Friday (T1-T4), and an 8-week follow-up period with short-term assessments immediately after the final stimulation session on Friday afternoon (T4) and long-term assessments after 2 weeks (FU2) and 8 weeks (FU8).
Objectives:
The primary objective is to assess the feasibility, safety and tolerability of cTBS in refractory epilepsy patients. The secondary objectives are to assess the clinical efficacy and associated mechanism of action of cTBS in unifocal neocortical epilepsy.
An open label prospective design allows to make a first estimate on the safety, feasibility and tolerability of cTBS in refractory epilepsy patients. There are currently no reports available of cTBS performed in epilepsy patients. The ultimate aim is to assess clinical efficacy of cTBS with regard to seizure frequency, but a feasibility and safety study is a prerequisite in order to achieve this goal.
255 studies on the registry are indexed under Epilepsies, Partial; 48 are open to participants now.
This study's enrollment of 7 is below the median of 86 across 198 interventional studies indexed under Epilepsies, Partial.
Browse Epilepsies, Partial studies →University Hospital, Ghent is the lead sponsor of 685 studies on the registry; 158 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with a vagus nerve stimulator are not excluded, provided that adequate distance between the coil and the implanted material can be maintained.
As the short duration of the study will not interfere with an ongoing presurgical evaluation and/or its eventual conclusion, the patients in the course of the evaluation or awaiting surgery are also eligible for inclusion.
Transcranial magnetic stimulation over the epileptogenic focus using a cTBS stimulation protocol.
Device: continuous thetaburst stimulation
On 4 consecutive days patients receive 5 cTBS trains with a 10min intertrain-interval. One cTBS train consists of 600 pulses delivered in bursts at theta frequency (200ms) during 40s. Each burst comprises 3 pulses at 50Hz. Focal stimulation occurs over the epileptogenic focus (EF), perpendicular to the local gyral geometry, using online neuronavigation. Stimulation intensity is set relative to the resting motor threshold (rMT) determined at baseline (80% rMT). Stimulation intensity is further adjusted to the coil-cortex distance at the EF with the following formula: adjusted MT% (AdjMT) = rMT + 2,7\*(DEF-DM1) \[DEF = distance over EF; DM1 = distance over M1\]. If rMT exceeds the capacity of the stimulator output, stimulation intensity is 100% of maximal stimulator output (MSO).
Also known as: rTMS, cTBS
Seizure induction
Induction of epileptic seizures during or in-between rTMS stimulation trains as a measure of safety
Time frame: Throughout stimulation, 4 days
Seizure diary
Self-reported seizure frequency throughout the study as a measure of clinical efficacy. Four separate seizure diaries are provided: * Baseline period: 4 weeks prior to treatment * Treatment week: from monday to friday evening * Follow-up part 1: two weeks following the treatment week * Follow-up part 2: week 3 to week 8 following treatment Patients note down if the seizure was habitual, atypical or if it was an episode of uncertain etiology (eg. non-epileptic)
Time frame: Throughout the study, lasting 13 weeks
Adverse events diary
Description of all experienced adverse event during the study as a measure of safety and tolerability.
Time frame: Throughout the study, lasting 13 weeks
Number of interictal epileptiform discharges (IEDs) on hd-EEG
A 15min hd-EEG is recorded and IEDs are counted during acquisition. Comparison of number of IEDs between the different time points as a measure of clinical efficacy.
Time frame: Throughout the study, lasting 13 weeks: baseline (before treatment), following final stimulation session (short-term follow-up), 2 weeks after stimulation and 8 weeks after stimulation (long-term follow-up)
Number of interictal epileptiform discharges (IEDs) on normal EEG
Fifteen min EEG with 21 scalp electrodes is recorded immediately before and following each stimulation session. Number of IEDs are counted and compared between pre- and post acquisition as a measure of clinical efficacy.
Time frame: Throughout the study, lasting 13 weeks: assessment immediately before and after each treatment session
Cortical resting motor threshold (rMT)
Cortical resting motor threshold is determined using single-pulse TMS over the primary motor cortex (M1) (ipsilateral to epileptogenic focus). Motor-evoked potential (MEP) is measured over the first dorsal interosseus (FDI) of the contralateral hand. Using a threshold tracking tool (Adaptive PEST) the minimally required stimulation intensity that elicits an MEP of 50 microvolt is determined. RMT at different time points throughout the study is compared to assess the effect of the treatment on cortical excitability as a measure of mechanism of action.
Time frame: Throughout the study, lasting 13 weeks: baseline (before treatment), following final stimulation session (short-term follow-up), 2 weeks after stimulation and 8 weeks after stimulation (long-term follow-up)
TMS-EEG evoked potentials (TEPs)
TMS-EEG evoked potentials are measured over the epileptogenic focus and the primary motor cortex by performing single-pulse TMS (100 consecutive pulses jittered around an interval of 5s) with continuous EEG acquisition. The EEG is processed in order to obtain quantitative and comparable TEPs measures that reflect cortical excitability. These TEP measures obtained at different time points throughout the study are compared to assess the effect of the treatment on cortical excitability as a measure of mechanism of action.
Time frame: Throughout the study, lasting 13 weeks: baseline (before treatment), following final stimulation session (short-term follow-up), 2 weeks after stimulation and 8 weeks after stimulation (long-term follow-up)
Magnetic resonance imaging (MRI)
Resting-state functional MRI (rs-fMRI) is acquired at the four main time points of the study to assess the effects of treatment on functional connectivity as a measure of mechanism of action.
Time frame: Throughout the study, lasting 13 weeks: baseline (before treatment), following final stimulation session (short-term follow-up), 2 weeks after stimulation and 8 weeks after stimulation (long-term follow-up)
High-density EEG (hd-EEG)
A 128-channel EEG for resting-state EEG acquisition is obtained at the four main time points of the study to assess the effects of treatment on functional connectivity as a measure of mechanism of action.
Time frame: Throughout the study, lasting 13 weeks: baseline (before treatment), following final stimulation session (short-term follow-up), 2 weeks after stimulation and 8 weeks after stimulation (long-term follow-up)
Change in Montreal Cognitive Assessment score (MoCA)
Score ranging from 0 \[worst cognitive state\] to 30 \[best cognitive state\], with a score of 26 or higher reflecting normal cognitive function. Cognitive assessment as a measure of safety: comparison at different time points throughout the study using MoCA version 7, 7.2 and 7.3 respectively.
Time frame: Throughout the study, lasting 13 weeks: baseline (before treatment), following final stimulation session (short-term follow-up) and 8 weeks after stimulation (long-term follow-up)
Change in Computerized Visual Searching Task (CVST)
A 24-figure task assessing mean trial time \[the faster the better\] and number of errors \[the lower the better\] Assessment of mental flexibility and information processing as a measure of safety: comparison at different time points throughout the study.
Time frame: Throughout the study, lasting 13 weeks: baseline (before treatment), following final stimulation session (short-term follow-up), 2 weeks after stimulation and 8 weeks after stimulation (long-term follow-up)
Change in Quality of life in epilepsy-31 (QOLIE-31)
Questionnaire scoring quality of life (QoL) ranged from 0 \[lowest QoL\] to 100 \[highest QoL\] (with associated T-value per score) as a measure of well-being.
Time frame: Throughout the study, lasting 13 weeks: baseline (before treatment) and 8 weeks after stimulation (long-term follow-up)
Change in Beck depression inventory (BDI-II)
Questionnaire scoring depression ranged from 0 to 63 as a measure of well-being.
Time frame: Throughout the study, lasting 13 weeks: baseline (before treatment) and 8 weeks after stimulation (long-term follow-up)
Change in Positive affect negative affect schedule (PANAS)
Questionnaire scoring affect as a measure of well-being.
Time frame: Throughout the study, lasting 13 weeks: baseline (before treatment) and 8 weeks after stimulation (long-term follow-up)
Change in State-trait anxiety inventory (STAI)
Questionnaire scoring anxiety as a state (now) or a trait (more generally) separately, ranged from 20 \[less anxious\] - 80 \[more anxious\] as a measure of well-being.
Time frame: Throughout the study, lasting 13 weeks: baseline (before treatment) and 8 weeks after stimulation (long-term follow-up)
Change in Visual analogue scale (VAS) of general well-being
Score ranged from 0 \[lowest well-being\] to 100 \[highest well-being\] as a measure of well-being.
Time frame: Throughout the study, lasting 13 weeks: baseline (before treatment) and 8 weeks after stimulation (long-term follow-up)
Change in Visual analogue scale (VAS) of tolerability of the treatment
Score ranged from 0 \[absolutely tolerable\] -100 \[absolutely intolerable\] as a measure of tolerability and feasibility.
Time frame: Throughout the study: after each treatment session and at the end of the study (8 weeks after stimulation)
Ran from Aug 2015 to primary completion in Apr 2018, 32 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.